Curosurf (Poractant Alfa)

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This product helps improve lung function and oxygenation, making it a critical treatment in neonatal care.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs do not produce enough surfactant, a substance that keeps the air sacs open. By replacing the missing surfactant, Curosurf helps to improve breathing and reduce the need for mechanical ventilation. It is administered directly into the lungs via endotracheal tube.

Curosurf works by coating the inner surface of the lungs, reducing surface tension and allowing the air sacs to remain open. This helps to improve oxygenation and reduce the work of breathing. Common effects include improved lung function and reduced need for respiratory support.

Curosurf should be used under the supervision of a healthcare professional. It is important to follow proper administration techniques to ensure effective treatment. Always store Curosurf according to the manufacturer's instructions to maintain its efficacy.

Curosurf is generally well-tolerated, but it is important to inform your healthcare provider about any other medications or treatments your infant is receiving. Always follow the advice of a healthcare professional regarding the use of Curosurf.